Gyre Therapeutics
GYRE
70 hedge funds and large institutions have $85.6M invested in Gyre Therapeutics in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 17 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.23% less ownership
Funds ownership: 9.1% → 8.87% (-0.23%)
7% less funds holding
Funds holding: 75 → 70 (-5)
10% less capital invested
Capital invested by funds: $95.2M → $85.6M (-$9.58M)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
80% less call options, than puts
Call options by funds: $679K | Put options by funds: $3.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$2.71M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.56M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.5M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.72M |
| 5 |
Two Sigma Investments
New York
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$9.69M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.01M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.64M |
| 4 |
Renaissance Technologies
New York
|
-$1.54M |
| 5 |
PE
Point72 Europe
London,
United Kingdom
|
-$974K |
GYRE Hedge Fund Activity: Q3 2018 in Review
70 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2018, worth a combined $85.6M — down 10% from $95.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of GYRE and 13 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 31 added.
The largest buyer was First Manhattan, opening a new position worth an estimated $2.71M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $9.69M sold.
- 70 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2018, down from 75 in Q2 2018.
- Funds reported $85.6M of Gyre Therapeutics stock for Q3 2018, down 10% quarter-over-quarter.
- 13 funds opened new Gyre Therapeutics positions in Q3 2018 and 17 closed out, a net change of -4 holders.
- The largest Gyre Therapeutics buyer in Q3 2018 was First Manhattan, an estimated $2.71M added.
- The largest Gyre Therapeutics seller in Q3 2018 was Acuta Capital Partners, an estimated $9.69M sold.
Based on aggregated 13F filings for Q3 2018.